Tiverton Asset Management’s United Therapeutics UTHR Stock Holding History

Tiverton Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-76,000	Closed	-$13.2M	–	156
2015 Q2	$13.2M	Hold	76,000	–	–	0.26%	96
2015 Q1	$13.1M	Hold	76,000	–	–	0.27%	92
2014 Q4	$9.84M	Hold	76,000	–	–	0.2%	102
2014 Q3	$9.78M	Hold	76,000	–	–	0.22%	93
2014 Q2	$6.73M	Hold	76,000	–	–	0.15%	104
2014 Q1	$7.15M	Hold	76,000	–	–	0.15%	107
2013 Q4	$8.59M	Hold	76,000	–	–	0.19%	99
2013 Q3	$5.99M	Hold	76,000	–	–	0.14%	103
2013 Q2	$5M	Buy	+76,000	New	+$4.9M	0.13%	99

Other funds holding UTHR

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Tiverton Asset Management's UTHR Position: Q3 2015 in Review

Tiverton Asset Management sold out of United Therapeutics (UTHR) in Q3 2015, closing a stake of 76,000 shares — an estimated $13.2M sold.

Tiverton Asset Management first reported a position in UTHR in Q2 2013 and held it in 9 quarters. The position peaked at $13.2M in Q2 2015. 372 funds tracked by Wall St. Rank hold UTHR as of Q3 2015.

Tiverton Asset Management reported no remaining United Therapeutics position as of Q3 2015 after selling out during the quarter.
Tiverton Asset Management sold 76,000 United Therapeutics shares in Q3 2015, an estimated $13.2M.
Tiverton Asset Management first reported a position in United Therapeutics in Q2 2013 and held it in 9 quarters.
Tiverton Asset Management's United Therapeutics position peaked at $13.2M in Q2 2015.
372 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2015.

Based on Tiverton Asset Management's 13F filing for Q3 2015, filed 12 Nov 2015.